David L. Rimm, M.D., Ph.D.



Professor of Pathology;
Director of Medical Studes; Director of Pathology Tissue Services.

Department of Pathology
Yale University School of Medicine
P.O. Box 208023
310 Cedar St., BML122A
New Haven, CT 06520-8023

Office: (203) 737-4204
Lab: (203) 737-4205
Fax: (203) 737-5089

email: david.rimm@yale.edu


Training:
B.S. (Molecular Biology/Honors) University of Wisconsin, Madison, WI, 1981
M.D.- Ph.D. (Cell Biology) Johns Hopkins School of Medicine, Baltimore, MD, 1989
Pathology Residency: Yale-New Haven Hospital 1989-93
Cytopathology Fellowship: Medical College of Virginia 1993-94


Expertise:
Quantitative Pathology, Cancer Tissue Biomarkers, Melanoma, Breast Cancer, Cell-cell adhesion in cancer, Translation of molecular techniques to diagnostic cytopathology. Other interests: General Cytopathology, Immunohistochemistry; thyroid pathology.

Research Interests:
The Rimm Laboratory spans a range of topics in 3 main areas including 1)basic issues; including regulation of cell adhesion and growth factor signaling, 2) translation issues; including tissue biomarkers, circulating cancer cells, tissue microarrays and digital pathology, and 3) clinical issues: including advanced objective diagnostics using novel information gathering technologies. Studies include:
1) Translational studies using tissue microarray technology and digital pathology algorithms (AQUA) to apply basic, rigorous molecular technology to diagnostic problems in pathology and cytopathology toward the goal of development of new predictive and prognostic tissue biomarkers.
2) Studies of the organization and regulation of the biochemical interactions occurring at the cytoplasmic face of the cadherin-based adhesion complex and Growth Factor Receptor complexes (focusing on Met and ErbB family) involving signal transduction and the cytoskeleton.
3) Analysis of micro-metastasis and circulating cancer cells in the peripheral blood for both diagnostic and prognostic applications.
4) Use of spectral analysis for tumor diagnosis and classification in surgical pathology and cytopathology


Professional Service:
American Society of Cytopathology (ASC):
ASC Executive Board 2002-2006
ASC Long Range Planning Committee 1999-2002
ASC Chair, Committee on New Technology 1998-2003
Editorial Advisory Board, Cancer Cytopathology 1996-present
Section Editor, Molecular Biology Section, Acta Cytologica 2000-2005
Tumor Cell Bio. II, Study Section Chair, Susan G. Komen Foundation 2000-2003
NIH Cancer Biomakers (CBSS) Study Section, Charter Member 10/03 � present
Immunohistochemistry Section Editor, Archives of Pathology 3/05 - current
Editorial Advisory Board, Journal of Pathology 2/05- current

Other Links:

Cytopathology
Rimm Lab
YCC Tissue Microarray Facility
HistoRx
Community of Science (COS) Database

Selected Publications:

Camp, R.L. Chung, G.G., and Rimm, D.L. (2002) Algorithms for Automated Tissue Microarray Analysis Reveal Novel Disease Sub-classifications. Nature Medicine 8(11):1323-8

Camp, R.L., Dolled-Filhart, M., King, B and Rimm, D.L. (2003) Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome. Cancer Research 63:1445-1448

Berger. A.J., Camp R.L., DiVito, K.A., Kluger, H.M., Halaban, R., and Rimm, D.L. (2004) Automated Quantitative Analysis (AQUA) of HDM2 Expression in Malignant Melanoma Shows Association with Early Stage Disease and Improved Outcome. Cancer Res 64(23):8767-72.

Camp R.L., Dolled-Filhart, M., and Rimm D.L. (2004) X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10(21):7252-9.

McCabe, A., M. Dolled-Filhart, R.L. Camp, and D.L. Rimm. (2005) Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 97:1808-15.

Pozner-Moulis, S., D.J. Pappas, and D.L. Rimm (2006) Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res 66, 7976-7982.

Rimm, D.L.. (2006) What brown cannot do for you (commentary) Nat Biotechnol 24, 914-916.

Pozner-Moulis S, Cregger M, Camp RL, Rimm DL(2007) Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 87(3):251-60

Search PubMed Database for David Rimm


This page was last modified on: 09/19/2008